share_log

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54

HC Wainwright & Co.維持對Cartesian Therapeutics的買入,將目標股價調整至54美元
Moomoo 24/7 ·  04/23 12:26

HC Wainwright & Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy, adjusts target to $54 from $2.

HC Wainwright & Co. 分析師米切爾·卡普爾維持Cartesian Therapeutics(納斯達克股票代碼:RNAC)的買入,將目標從2美元調整至54美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論